Alzamend Neuro director William B. Horne purchases $4,891 in shares

Published 20/03/2025, 21:32
Alzamend Neuro director William B. Horne purchases $4,891 in shares

In a recent transaction reported to the Securities and Exchange Commission, William B. Horne, a director at Alzamend Neuro , Inc. (NASDAQ:ALZN), purchased 5,000 shares of the company’s common stock. The micro-cap biotech firm, currently valued at $6.4 million, has seen its shares surge nearly 38% over the past week, according to InvestingPro data. The shares were acquired in open market transactions on March 20, 2025, at a volume-weighted average price of $0.9783 per share, with purchase prices ranging from $0.974 to $0.9799 per share. Following this transaction, Horne’s direct ownership in Alzamend Neuro increased to 26,666 shares. The company maintains strong liquidity with a current ratio of 5.44, and InvestingPro analysis suggests the stock is currently undervalued. For deeper insights into ALZN’s valuation and 12 additional ProTips, visit InvestingPro.

In other recent news, Alzamend Neuro has announced several significant developments. The company has entered into an agreement for selling and exchanging equity securities with a sophisticated investor, potentially reaching a total purchase price of up to $5 million. This deal involves the exchange of Series A Convertible Preferred Stock for Series C Convertible Preferred Stock, and the sale of up to 500 shares of Series C Preferred Stock, along with warrants to purchase common stock. The Series C Preferred Stock has a stated value of $10,000 per share and offers cumulative cash dividends at an annual rate of 15%. Additionally, Alzamend Neuro has amended its corporate bylaws to reduce the quorum requirement for stockholder meetings from a majority to 35% of the outstanding capital stock entitled to vote. The company has also completed a specialized head coil for its upcoming Phase II clinical trials, which will compare the pharmacokinetics of their product AL001 against traditional lithium carbonate. This innovation is expected to aid in determining optimal dosages for treating neurological and psychiatric conditions. Alzamend Neuro’s collaboration with Massachusetts General Hospital will oversee these trials, aiming to optimize lithium distribution in the brain.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.